Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

TPX2 drives cell cycle progression and impairs immune cell communication in lung cancer based on multi-omics evidence

ABSTRACT: Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide. Despite significant advancements in diagnosis and treatment, its mortality rate persists at alarmingly high levels. TPX2, a critical cell cycle regulatory protein, has been reported to exhibit aberrant expression in various malignancies, yet its specific mechanistic role in lung cancer remains poorly understood. To elucidate the mechanism of TPX2-driven lung cancer and identify its downstream transcriptional targets, we conducted genome-wide RNA sequencing in A549 cells knockdowning TPX2, with comparison to negative control (sh-NC) group.

ORGANISM(S): Homo sapiens

PROVIDER: GSE333209 | GEO | 2026/08/31

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

TPX2-mediated autophagy maintains cancer stemness in LUAD

Project description:Targeting protein for Xklp2 (TPX2) is a mitotic regulator frequently overexpressed in lung adenocarcinoma (LUAD), while its role in cancer stemness and autophagy remains incompletely understood. In this study, integrative bioinformatic analyses based on TCGA and GTEx datasets revealed that TPX2 overexpression in LUAD was associated with poor prognosis, elevated stemness scores, and increased expression of cancer stem cell-related markers. To investigate the molecular mechanisms underlying TPX2-mediated regulation in LUAD, RNA sequencing was performed in PC9 cells following TPX2 knockdown. Transcriptomic profiling and pathway analyses identified significant alterations in autophagy-related signaling pathways. In parallel, co-immunoprecipitation coupled with mass spectrometry (IP-MS) was conducted to characterize TPX2-associated protein interactions and explore potential regulatory networks involved in autophagy. Functional experiments further demonstrated that TPX2 depletion impaired autophagic flux and reduced stemness-associated phenotypes in LUAD cells, whereas TPX2 overexpression exerted opposite effects. These data provide transcriptomic and proteomic resources for investigating the role of TPX2-mediated autophagy in LUAD progression and cancer stemness.

2026-05-28 | GSE333531 | GEO

TPX2-mediated autophagy maintains cancer stemness in LUAD

Project description:TPX2-mediated autophagy maintains cancer stemness in LUAD

| PRJNA1471262 | ENA

TPX2 Amplification-Driven Aberrant Mitosis in Long-Term Cultured Human Embryonic Stem Cells

Project description:Although human embryonic stem cells (hESCs) are equipped with highly effective machinery for the maintenance of genome integrity, the frequency of genetic aberrations during long-term in vitro hESC culture has been a serious issue that raises concerns over their safety in future clinical applications. By passaging hESCs over a broad range of timepoints, we found that mitotic aberrations, such as the delay of mitosis, multipolar centrosomes, and chromosome mis-segregation, were increased in the late-passaged hESCs (LP-hESCs) in parallel with polyploidy compared to early-passaged hESCs (EP-hESCs). Through high-resolution genome-wide approaches and by following transcriptome analysis, we found that LP-hESCs with a minimal amplicon in chromosome 20q11.21 highly expressed TPX2 (targeting protein for Xklp2), a key protein for governing spindle assembly and cancer malignancy. Consistent with these findings, the inducible expression of TPX2 in EP-hESCs reproduced aberrant mitotic events, such as the delay of mitotic progression, spindle stability, misaligned chromosomes, and polyploidy. This data suggests that the amplification and increased transcription of the TPX2 gene at 20q11.21 could contribute to an increase in aberrant mitosis due to altered spindle dynamics.

2021-02-26 | GSE167495 | GEO

RNA-seq to investigate gene expression profiles in tumor infiltrating CD8+ T cells with TPX2-overexpression

Project description:CD8+ T cells were isolated from fresh human HCC tissues, then treated with lentivirus for TPX2 over-expression or control

2024-02-15 | E-MTAB-10040 | biostudies-arrayexpress

MicroRNA-224 promotes tumor progression in non-small cell lung cancer

Project description:Lung cancer is the leading cause of cancer-related deaths worldwide. Despite advancements and improvements in surgical and medical treatments, the survival rate of lung cancer patients remains frustratingly poor. Local control for early stage non-small cell lung cancer (NSCLC) has dramatically improved over the last decades for both operable and inoperable patients. However, the molecular mechanisms of NSCLC invasion leading to regional and distant disease spread remain poorly understood. Here we identify miR-224 to be significantly up-regulated in NSCLC tissues, in particular in resected NSCLC metastasis. Increased miR-224 expression promotes cell migration, invasion and proliferation by directly targeting the tumor suppressors, TNFAIP1 and SMAD4. In concordance with in vitro studies, mouse xenograft studies validated that miR-224 function as a potent oncomiR in NSCLC in vivo. Moreover, we found promoter hypomethylation and activated ERK signaling to be involved in the regulation of miR-224 expression in NSCLC. Up-regulated mir-224 thus facilitates tumor progression by shifting the equilibrium of the partially antagonist functions of SMAD4 and TNFAIP1 towards enhanced invasion and growth in NSCLC. Our findings indicate that targeting miR-224 could be effective in the treatment of certain lung cancer patients Oncogenic role of miR-224 in lung cancer

2015-07-01 | E-GEOD-64859 | biostudies-arrayexpress

TPX2 as key downstream target of the eIF4A controlled translational program in MYCN driven neuroblastoma [MYCN_CutAndRun]

Project description:Current therapies for neuroblastoma are often ineffective and survivors suffer from severe long-term therapy related side-effects, underscoring the need for identification of novel drugging strategies. We performed an in-depth evaluation of phenotypic and molecular responses following exposure of neuroblastoma cells to the rocaglate CR-1-31-B, scrutinizing its mode-of-action through integrative ribosome footprinting and shotgun proteome profiling. We could show that CR-1-31-B significantly reduces tumor growth in vivo without apparent toxicity. By means of combined ribosome footprint and transcriptome analysis we could show that CR-1-31-B treatment induces downregulates factors involved in the G2/M checkpoint, while upregulated targets are enriched for oxidative phosphorylation pathway components and DNA repair. At the proteome level, CR-1-31-B revealed downregulation of a FOXM1 driven gene signature, with TPX2 as prominent marker. Knockdown of TPX2 leads to reduced neuroblastoma cell confluence and elevated levels of DNA damage. In conclusion, our data support CR-1-31-B as a potent novel therapeutic agent in neuroblastoma.

2026-02-01 | GSE246722 | GEO

TPX2 as key downstream target of the eIF4A controlled translational program in MYCN driven neuroblastoma[RNA-Seq]

2026-02-01 | GSE246725 | GEO

MYC Dysregulates Mitotic Spindle Function Creating a Dependency on TPX2

Project description:MYC Dysregulates Mitotic Spindle Function Creating a Dependency on TPX2

| PRJNA541944 | ENA

miR-291a-3psuppresseslungcancerproliferation,invasion,andmigrationbytargeting relevantgenes.

Project description:Lung cancer is the leading cause of cancer-related mortality worldwide, and overall patient prognosis remains poor. MicroRNAs function as either tumor suppressors or oncogenes and are critically involved in various stages of lung cancer development and progression. However, the functional role and underlying mechanisms of miR-291a-3p in lung cancer remain largely unknown.

2026-01-25 | GSE316995 | GEO

Proteome of silenced minichromosome maintenance protein 2 with siRNA on non-small cell lung cancer H1299 cells

Project description:Lung cancer is the leading cause of cancer-related mortality. The two main lung cancer types are small cell lung cancer (SCLC) and non-SCLC (NSCLC), where NSCLC comprises about 80-85% of all lung cancer. Despite the introduction of improved treatments, the overall survival rate of lung cancer patients remains low. Further elucidation of the regulatory network perturbations between cancer-related genes and proteins is one promising route to alter this mortality trend. The deregulation of the DNA replication, cell cycle, proliferation and migration are the common factors that are involved in cancer development and progression, and therefore logical targets for analysis. Minichromosome maintenance 2(MCM2) is a DNA replication licensing factor, which belongs to the heterohexameric MCM2-7 complex. MCM2 has been proposed as an excellent proliferation marker in many types of cancer. Our study will establish a global functional distribution of identified proteins in silenced-MCM2 in H1299 NSCLC by the means of iTRAQ. Understanding the molecular basis of MCM2 in lung cancer cells enables us to discover alternative target for lung cancer therapy.

2018-10-26 | PXD003743 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data